Treatment choices for diabetic macular oedema: a guideline for when to consider an intravitreal corticosteroid, including adaptations for the COVID-19 era

First-line treatment of centrally involved diabetic macular oedema (CI-DMO) is often with an anti-vascular endothelial growth factor (anti-VEGF) agent. Although this can provide efficacy in the majority of eyes, a sizeable proportion do not respond sufficiently and many continue to receive anti-VEGF...

Descripción completa

Detalles Bibliográficos
Autores principales: Downey, Louise, Acharya, Nachiketa, Devonport, Helen, Gale, Richard, Habib, Maged, Manjunath, Vina, Mukherjee, Rajarshi, Severn, Philip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088120/
https://www.ncbi.nlm.nih.gov/pubmed/34192155
http://dx.doi.org/10.1136/bmjophth-2020-000696

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088120/
https://www.ncbi.nlm.nih.gov/pubmed/34192155
http://dx.doi.org/10.1136/bmjophth-2020-000696

Ejemplares similares